Home › Calculator › CANF Dividend Calculator 2026
CANF Dividend DRIP Calculator 2026
59.70% YieldHealthcareCan-Fite BioPharma Ltd. · AMEX
Price: $3.35 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When CANF pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your CANF snowball 📈
$10,000 in CANF → $1457.75M in 10 years · $112,338,022.48/month
About Can-Fite BioPharma Ltd. (CANF) — Dividend Analysis 2026
Can-Fite BioPharma Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in the creation of small molecule therapeutic products. These treatments target a range of conditions including various cancers, inflammatory liver disorders, and erectile dysfunction. Its primary drug candidate, Piclidenoson, has successfully advanced through Phase III clinical trials for psoriasis and completed Phase II trials for COVID-19. Another promising asset, Namodenoson, is currently undergoing Phase III clinical evaluation for hepatocellular carcinoma (a form of liver cancer) and is in a Phase IIb study for non-alcoholic steatohepatitis (NASH). Furthermore, CF602 is in preclinical development, aimed at addressing erectile dysfunction. Beyond its drug pipeline, Can-Fite also commercializes a predictive biomarker blood test kit for A3AR. Strategic partnerships are also key to its operations; a licensing and collaboration agreement with CMS Medical covers the development, manufacturing, and commercialization of both Piclidenoson and Namodenoson. Additionally, the company collaborates with Univo Pharmaceuticals to identify and co-develop cannabis-derived formulations intended for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic conditions. Originally incorporated in 1994 as Can-Fite Technologies Ltd., the company adopted its current name, Can-Fite BioPharma Ltd., in January 2001 and is headquartered in Petah Tikva, Israel.
Compare CANF with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full CANF DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open CANF position with:
🌍 CANF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold CANF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 59.70% | 56.90% | $5,970 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 50.75% | 47.95% | $5,075 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 47.76% | 44.96% | $4,776 / yr |
| 🇬🇧 UK ISA | 0% | 59.70% | 56.90% | $5,970 / yr |
| 🇬🇧 UK Taxable | 8.75% | 54.48% | 51.68% | $5,448 / yr |
| 🇨🇦 TFSA | 0% | 59.70% | 56.90% | $5,970 / yr |
| 🇨🇦 CA Taxable | 25% | 44.78% | 41.98% | $4,478 / yr |
| 🇦🇺 Super (pension) | 15% | 50.75% | 47.95% | $5,075 / yr |
| 🇦🇺 AU Taxable | 30% | 41.79% | 38.99% | $4,179 / yr |
| 🇩🇪 DE Taxable | 26.375% | 43.95% | 41.15% | $4,395 / yr |
| 🇫🇷 FR Taxable | 30% | 41.79% | 38.99% | $4,179 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 CANF Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 CANF Dividend Payment Schedule
CANF pays quarterly — 4 times per year. Next ex-div: TBD.
📊 CANF vs Healthcare Benchmarks
How CANF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for CANF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ CANF Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-06-04 | 24,000 | $2.04 | $49.0K | ||
| A-Award | 2026-06-04 | 24,000 | $2.04 | $49.0K | ||
| Other | 2026-04-25 | 16,000 | $2.25 | $36.0K | ||
| Other | 2017-02-08 | 16 | $2826.14 | $45.2K | ||
| Other | 2020-06-15 | 200 | $241.47 | $48.3K | ||
| Other | 2023-08-01 | 2,166 | $25.21 | $54.6K | ||
| Other | 2024-08-07 | 2,166 | $26.56 | $57.5K | ||
| Other | 2026-04-25 | 16,000 | $2.18 | $34.9K | ||
| Other | 2021-06-22 | 200 | $241.47 | $48.3K | ||
| Other | 2023-08-01 | 2,166 | $25.21 | $54.6K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the CANF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Can-Fite BioPharma Ltd. (CANF) is currently trading at $3.35, 99% below its 52-week high. The current dividend yield is 59.70% based on an annual payout of $2.00 per share.
CANF (Can-Fite BioPharma Ltd.) — 59.70% Dividend Yield Analysis
Can-Fite BioPharma Ltd. (CANF) is a healthcare stock currently trading at $3.35 with a dividend yield of 59.70%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (59.70%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.